UI 031
Alternative Names: UI-031Latest Information Update: 23 Jun 2022
At a glance
- Originator Korea United Pharm Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Chronic obstructive pulmonary disease
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease
Most Recent Events
- 24 May 2022 UI 031 is available for licensing as of 24 May 2022. https://www.kup.co.kr/research/innovation_main.htm
- 24 May 2022 Preclinical trials in Chronic obstructive pulmonary disease in South Korea (Inhalation) (Korea United Pharm pipeline, May 2022)